Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism
- 1 September 2004
- journal article
- Published by Elsevier in Seminars in Nephrology
- Vol. 24 (5) , 456-459
- https://doi.org/10.1016/j.semnephrol.2004.06.013
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Vitamin D Analogs: Perspectives for TreatmentMineral and Electrolyte Metabolism, 1999
- Pathogenesis of secondary hyperparathyroidismKidney International, 1999
- 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failureKidney International, 1999
- In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-6F-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levelsXenobiotica, 1999
- Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25- dihydroxyvitamin D2American Journal of Kidney Diseases, 1998
- Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 1998
- Unique 24-Hydroxylated Metabolites Represent a Significant Pathway of Metabolism of Vitamin D2 in Humans: 24-Hydroxyvitamin D2 and 1,24-Dihydroxyvitamin D2 Detectable in Human SerumJournal of Clinical Endocrinology & Metabolism, 1998
- A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemiaAmerican Journal of Kidney Diseases, 1995
- Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal FailureNew England Journal of Medicine, 1989
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Journal of Clinical Investigation, 1984